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Abstract. Glucosylceramide (GlcCer) is synthesized at 
the cytosolic surface of the Golgi complex while en- 
zymes acting in late steps of glycosphingolipid biosyn- 
thesis have their active centers in the Golgi lumen. 
However, the topology of the "early" galactose-trans- 
ferring enzymes is largely unknown. We used short- 
chain ceramides with either a 2-hydroxy fatty acid 
(HFA) or a normal fatty acid (NFA) to determine the 
topology of the galactosyltransferases involved in the 
formation of HFA- and NFA-galactosylceramide (Gal- 
Cer), lactosylceramide (LacCer), and galabiosylcera- 
mide (GaECer). 
Although the HFA-GaICer synthesizing activity 
colocalized with an ER marker, the other enzyme activ- 
ities fractionated at the Golgi density of a sucrose gra- 
dient. In cell homogenates and permeabilized cells, 
newly synthesized short-chain GlcCer and GalCer were 
accessible to serum albumin, whereas LacCer and 
Ga2Cer were protected. From this and from the results 
obtained after protease treatment, and after interfering 
with UDP-Gal import into the Golgi, we conclude that 
(a) GlcCer and NFA-GaICer are synthesized in the cy- 
tosolic leaflet, while LacCer and GaECer are synthe- 
sized in the lumenal leaflet of the Golgi. (b) HFA-Gal- 
Cer is synthesized in the lumenal leaflet of the ER, but 
has rapid access to the cytosolic leaflet. (c) GlcCer, 
NFA-GaICer, and HFA-GaICer translocate from the 
cytosolic to the lumenal leaflet of the Golgi membrane. 
The transbilayer movement of GlcCer and NFA-Gal- 
Cer in the Golgi complex is an absolute requirement 
for higher glycosphingolipid biosynthesis and for the 
cell surface expression of these monohexosyl sphin- 
golipids. 
LYCOSPHINGOLIPIDS are universal membrane com- 
ponents of eukaryotic cells. They are enriched at 
the  cell  surface and in the lumen  of endosomes 
and  lysosomes (60).  At  the  cell surface the  glycosphin- 
golipids not only exert functions in cell-cell interaction, 
cell-substrate interaction, and signal transduction, but are 
also used as receptors by bacteria, bacterial toxins, and vi- 
ruses. Glycosphingolipids are a relatively minor constitu- 
ent of most membranes, but a major component of myelin 
and of the apical plasma membrane of the polarized epi- 
thelial cells that line the gastrointestinal and urinary tract. 
In the latter  tissues, glycosphingolipids play a  structural 
role in rigidifying  and protecting the cell surface. The api- 
cal plasma membrane  of polarized  epithelial  cells  is en- 
riched  in  glycosphingolipids  relative  to  the  basolateral 
plasma membrane which contains less glycosphingolipids 
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but more of the phospholipid phosphatidylcholine and the 
(sphingo)phospholipid  sphingomyelin  (SM).  t  Studies us- 
ing epithelial cells in culture indicate that glycosphingolip- 
ids  and  phospholipids  are  sorted  intracellularly  before 
reaching  the  cell  surface.  Moreover,  glycosphingolipids 
are thought to play a key role in the sorting of lipids  and 
proteins  to  the  appropriate  plasma  membrane  domain 
(61). For our understanding of the molecular mechanisms 
that  underlie  biosynthesis,  transport  and  sorting  of gly- 
1. Abbreviations used in this paper. Ga2Cer, galabiosylceramide, Gal ed-4 
Ga1131-1 Cer; GaiCer, galactosylceramide,  Gal 131-1 Cer; GalT-1, UDP- 
galactose:ceramide galactosyltransferase; GaiT-2,  UDP-galactose:gluco- 
sylceramide  galactosyltransferase;  GalT-2b,  UDP-galactose:galactosyl- 
ceramide galactosyltransferase; GlcCer, glucosylceramide,  Glc 131-1 Cer; 
GlcT, UDP-glucose:ceramide glucosyltransferase; GST, PAPS:galactosyl- 
ceramide sulfotransferase; HFA, 2-hydroxy fatty acid;  LacCer, lactosyl- 
ceramide, Gal 131-4 GIc 131-1 Cer; M6P, mannose-6-phosphate; NFA, nor- 
mal  (nonhydroxy)  fatty  acid;  N-Rh-PE,  N-(lissamine  rhodamine  B 
sulfonyl) dioleoyl  phosphatidylethanolamine; PAPS,  3'-phosphoadeno- 
sine 5'-phosphosulfate; SGalCer, sulfatide,  HSO3-3 Gal IM-1 Cer; SM, 
sphingomyelin. 
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lar location and the topology of the enzymes involved in 
glycosphingolipid biosynthesis. 
Most glycosphingolipids, including virtually all ganglio- 
sides and globosides, are based on lactosylceramide (Lac- 
Cer), which is formed by galactosylation of the monohexo- 
syl sphingolipid, glucosylceramide (GlcCer). The second 
major  monohexosyl  sphingolipid  is  galactosylceramide 
(GalCer). In man, GalCer is particularly abundant in the 
epithelia of the intestine and kidney, and in the myelinat- 
ing tissue of the nervous system. GalCer is the precursor of 
the gala-series of glycosphingolipids which includes gala- 
biosylceramide  (Ga2Cer)  and  sulfatide  (SGalCer).  All 
sphingolipids are derived from ceramide (Cer), and though 
the final step in ceramide biosynthesis has not been local- 
ized yet, the last but one step, the formation of dihydro- 
ceramide occurs at the cytosolic surface of the ER (26, 35). 
After reaching the  Golgi complex, where most enzymes 
involved in sphingolipid biosynthesis are localized, cera- 
mide has access to both membrane leaflets by rapid spon- 
taneous transbilayer movement because  it lacks a  polar 
headgroup. The ceramide receives a polar headgroup ei- 
ther at the lumenal or the cytosolic face of the Golgi mem- 
brane: the active center of SM-synthase is located in the 
lumen, and the formation of GlcCer by the ceramide glu- 
cosyltransferase (GlcT) is located at the cytosolic surface 
(15, 20, 28, 55). The cytosolic orientation of GIcT has di- 
rect consequences for the mechanism by which GlcCer is 
transported to the cell surface: at some stage during trans- 
port it must undergo transbilayer movement towards the 
lumenal  or  exoplasmic  leaflet.  Moreover,  it  has  been 
shown that after conversion of GlcCer into LacCer by the 
galactosyltransferase GalT-2, subsequent steps in ganglio- 
side biosynthesis occur in the lumenal leaflet of the Golgi 
(for review see 59).  Thus, depending on the topology of 
GalT-2, ganglioside biosynthesis requires translocation of 
either  GlcCer  or  LacCer to  the  lumenal  leaflet  of the 
Golgi membrane. 
Conflicting results have been reported on the topology 
of GalT-2 (12,  16, 33, 55),  but the most recent data (33) 
support  a  lumenal orientation of GalT-2 indicating that 
ganglioside biosynthesis depends on translocation of GlcCer 
to the lumenal leaflet of the Golgi membrane. One aim of 
the current study was to provide additional evidence for a 
lumenal orientation of GalT-2, and to compare the topol- 
ogy of GAIT-2 with that of GaIT-l, the enzyme responsible 
for the forlgation of GalCer. To this end, we extended an 
earlier study on the topology of SM-synthase and GIcT 
(28),  and c[etermined the intracellular location and topol- 
ogy of Ga|T-1 and GAIT-2 in human liver-derived HepG2 
ceils.  Our second aim was to determine the intracellular 
location and the topology of the enzymes involved in the 
biosynthesis of glycosphingolipids based on GalCer. For 
this, we switched to dog kidney MDCK II cells which ex- 
press GalCer, Ga2Cer, and SGalCer (11, 23, 39). Because 
GalCer and its derivatives often contain a 2-hydroxy fatty 
acid (HFA) instead of a nonhydr0xy fatty acid (NFA), we 
characterized  glycosphiogolipid biosynthesis  both  using 
NFA-  and HFA-ceramide analogues.  Our  data indicate 
that  newly  synthesized  monohexosyl  sphingolipids  are 
present at the cytosolic surface of the ER and Golgi, and 
translocate from the cytosolic to the lumenal leaflet of the 
Golgi membrane in order to be used for higher glycosphin- 
golipid biosynthesis. 
Materials and Methods 
Materials 
UDP-GIc,  UDP-Gal,  3'-phosphoadenosine  5'-phosphosulfate  (PAPS), 
mannose-6-phosphate  (M6P),  egg phosphatidylcholine,  and  BSA  (frac- 
tion V) were obtained from Sigma Chem. Co. (St. Louis, MO).  Cell cul- 
ture media and solutions were from Gibco (Glasgow,  UK),  and culture 
plastics from Costar Corp. (Cambridge, MA). Tunicamycin was from Boeh- 
ringer Mannheim Corp. (Mannheim, FRG); pronase E  (3,640 U/rag), sa- 
ponin, and TLC-plates (Si60) from Merck (Darmstadt, FRG); CHAPS from 
Serva (Heidelberg, FRG); and Triton X-100 from Fluka (Buchs, FRG). 
N-6(7-nitro-2,1,3-benzoxadiazol-4-yl) -aminohexanoyl-ceramide  (NBD-Cer) 
was purchased  from Molecular  Probes  (Eugene,  OR)  and N-(lissamine 
rhodamine  B  sulfonyl)  dioleoyl  phosphatidylethanolamine  (N-Rh-PE) 
was from Avanti Polar-Lipids (Birmingham, AL). NBD-analogues of SM, 
GlcCer, GalCer, and LacCer were synthesized from NBD-hexanoic acid as 
before (62). Hexanoyl NFA-[14C]-Cer  was synthesized by coupling o-erythro- 
sphingosine to [14C]-hexanoic acid (specific activity 0.15 MBq/p,  mol), and 
hexanoyl  HFA-[3H]-Cer  was  synthesized  by  tritiating  I>erythro-sphin- 
gosine and coupling the resulting D-[4,5-3H]-sphinganine to t~,L-2-hydroxy 
hexanoic acid; the natural D-stereoisomer of HFA-[3H]-Cer  (specific ac- 
tivity 201 MBq/i.Lmol)  was used after purification (58). HFA-[aH]-GalCer 
was isolated from MDCK II cells incubated with HFA-[3H]-Cer and purified 
by two-dimensional TLC. L,I)-threo-PDMP (1-phenyl-2-decanoylamino-3- 
morpholino-l-propanol) was obtained from Matreya (Pleasant Gap, PA) 
and streptolysin-O was from Wellcome Diagnostics (Dartford, UK). 
Cells 
Cells were grown on plastic culture  dishes,  HepG2  cells in MEM  with 
10% FCS (53), CHO mutants Lec2 and Lec8 (Amer. Type Culture Collec- 
tion, Rockville, MD) in MEM-et with 10% FCS (52) and D6P2T cells (5), 
a gift from S.E. Pfeiffer (Farmington, ClP), in DMEM with 5% FCS. The 
medium was refreshed one day before the experiment, monolayers were 
80-90%  confluent. MDCK strain II cells (34), originally from K. Simons 
(Heidelberg), were grown in MEM with 5% FCS; confluent monolayers 
were used 3--4 d after seeding. 
Determination of Sphingolipid Synthesis 
Sphingolipid synthesis was determined  using the hexanoyl lipids, NBD- 
Cer,  NBD-GIcCer,  NBD-GalCer,  NFA-[14C]-Cer,  HFA-[3H]-Cer,  or 
HFA-[3HI-GalCer as the precursor. Nucleotide sugars, PAPS and MnC12, 
were used at a concentration of 1, 0.3, and 2 mM, respectively. NBD-Cer 
was added in vesicles (62), the other ceramide analogues from 10-times 
concentrated stocks in 0.3% BSA (41). 
Lipids were extracted according to Bligh and Dyer (8). All aqueous so- 
lutions were acidified to 10 mM acetic acid. When appropriate, KCI was 
added  (0.44 wt/vol %) to force SGalCer into the chloroform phase; the 
aqueous phase was washed with chloroform, and applied to a SepPak C18 
cartridge (Waters, Milford, MA) to recover any residual SGalCer present 
in the aqueous phase. Lipids were eluted from the column using chloro- 
form/methanol/water  (112.2/0.L vol/vol)  and  methanol.  Samples  were 
dried under nitrogen, and applied to TLC-plates using chloroform/methanol 
(2/1, vol/vol) and in the case of samples containing SGalCer, chloroform/ 
methanol/water (1/2.2/0.1,  vol/vol). Lipids were separated by two-dimen- 
sional TLC on borate-treated TLC plates (29), using in the first dimension 
chloroform/methanol/ammonia  (25%)/water,  65:35:4:4  (vol/vol),  and  in 
the second dimension chloroform/acetone/methanol/acetic acid/water, 50: 
20:10:10:5  (vol/vol). Radioactive lipids were detected by autoradiography 
after dipping the TLC plates in 0.4%  PPO dissolved in 2-methylnaphtal- 
ene supplemented with 10% xylene (9); preflashed Kodak X-Omat S films 
were exposed for 2-4 d  at  -80°C.  Radioactive lipid spots were scraped 
and quantified by liquid scintillation counting in a mixture of 0.3 ml Solu- 
lyte  (Baker,  Deventer, NL)  and  3  ml Ultima  Gold  (Packard,  Downers 
Grove, IL); background did not exceed 100 dpm [3H] and 50 dpm [14C]. 
Fluorescent lipid spots were quantified and corrected for background (1 
pmol NBD-lipid or less) as described before (62). 
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Cells  were  washed,  scraped,  and  homogenized  using  a  tight-fitting 
Dounce. A  postnuclear supernatant (PNS) was prepared by a 10-min spin 
at 375 gmar In experiments directly performed on a  PNS, buffer A  (120 
mM K+-glutamate, 15 mM KCI, 5 mM NaCI, 0.g mM CaCI2, 2 mM MgCI~, 
1.6 mM EGTA, 20 mM Hepes/KOH, pH 7.2) was used as the homogeni- 
zation buffer. In subfractionation experiments, cells were allowed to swell 
in a low salt buffer (10 mM Hepes-NaOH, 15 mM KCI, 1.5 mM MgCI2, pH 
7.2; 750 I~1 per 9-cm dish) for 15 min on ice, scraped, and homogenized in 
the same buffer (53). The PNS from one 9-cm dish (750 Ixl, 1-1.5 mg pro- 
tein) was layered on top of a linear sucrose gradient (0.7-1.5 M sucrose in 
1 mM EDTA, 10 mM Hepes-NaOH, pH 7.2) and the ll-ml gradient was 
centrifuged (SW41, 3 h, 38,000 rpm, 4°C). N-Rh-PE was used as a plasma 
membrane marker  (31):  cells  were  incubated with  2  ~M  N-Rh-PE  in 
HBSS-Hepes (HBSS, 10 mM Hepes-NaOH, pH 7.2) for 30 rain at 0°C and 
washed with PBS (0°C). The rhodamine content of each gradient fraction 
was determined after lipid extraction and TLC (hEx and k~m of 563 and 
585 nm). Gradient fractions were analyzed by incubating 250 Ixl aliquots 
for 45 min at 37°C in the presence of MnCI  2 with 10 nmol NBD-Cer and 
UDP-Glc to monitor synthesis of SM and GlcCer; with 10 nmol NBD-Cer 
or 5 nmol NFA-[14C]-Cer and UDP-Gal to monitor synthesis of SM and 
GalCer; with 0.6 nmol NBD-GIcCer and UDP-Gal to monitor synthesis  of 
LacCer; with 50 pmol HFA-[3H]-Cer, UDP-Glc, and UDP-Gal to monitor 
synthesis of HFA-SM, HFA-GlcCer, and HFA-GalCer; and with 4 pmol 
HFA-[3H]-GalCer,  UDP-Gal, and PAPS to monitor synthesis of HFA- 
Ga2Cer and HFA-SGalCer. The distribution of calnexin, an ER marker, 
was determined by Western blotting using polyclonal  antibodies  (22), 
125I-protein-A, and phosphorimage analysis. Protein concentrations were 
determined using the BCA method (Pierce, Rockford, IL). 
Sidedness in Permeabilized  Cells 
HepG2 monolayers were permeabilized using streptolysin-O (SLO) as de- 
scribed before (28), with some modifications: 1 U  SLO (2 ml) was used 
per 6-cm culture dish, and cells were permeabilized in buffer A. Permeabi- 
lized and intact (control)  cells were incubated at 10°C in 2 ml buffer A 
containing 26 nmol NBD-Cer and either UDP-GIc or UDP-Gal. After 3 h, 
the medium was replaced by 2 ml 1% (wt/vol) BSA in buffer A (t =  0) and 
the depletion of cellular NBD-lipids was followed at 10°C by renewing the 
BSA medium after 30 min, 1.5, 2.5, and 3.5 h. During the total incubation 
time of 6.5 h, a maximum of 30% of the cells detached. Before lipid analy- 
sis, the media were centrifuged (10 rain, 375 gmax,  4°C) to pellet these cells. 
After the 3.5-h incubation with BSA, cells were scraped and analyzed to- 
gether with the cell pellets. The sum of the fluorescence signals recovered 
from the synthesis medium, the BSA media, and the cells was set at 100%; 
the cell-associated fluorescence at each time point was then calculated by 
subtracting from this total the relative amount of fluorescence found in 
the media collected so far. It is important to note that only little additional 
NBD-lipid synthesis occurs during the BSA depletion (28). 
Sidedness in Cell Homogenates 
1 ml PNS (final volume; 1-2 mg protein) was incubated for 3 h at 10°C or 
for 30 min at 37°C with 26 nmol NBD-Cer or 75 pmol HFA-[3H]-Cer, in 
the presence of UDP-GIc, UDP-Gal, MnCI2,  and (in some cases) PAPS. 
In a second set of experiments, higher glycosphingolipids were allowed to 
form for 30 min at 37°C, from 37 pmol HFA-[3H]-GalCer  or 2.2 nmol 
NBD-GalCer in the presence of UDP-Gal and PAPS, or from 2.2 nmol 
NBD-GIcCer and UDP-Gal. The sidedness of short-chain sphingolipids 
was determined using depletion by BSA or selective destruction of NBD- 
fluorescence by dithionite. 
Depletion by BSA.  1 ml 10% (wt/vol) BSA in buffer A, with or without 
0.2% (wt/vol) saponin, was added, and the sample incubated for 30 rain on 
ice (unless stated otherwise). In another set of experiments, the depletion 
of short-chain sphingolipids by BSA was followed in time at 10°C. After 
BSA treatment, the sample (2 ml) was loaded on top of a 2-ml 0.4 M su- 
crose cushion (1 mM EDTA, 10 mM Hepes-NaOH, pH 7.2) and centri- 
fuged (SW60, 30 min, 50,000 rpm, 4°C). About 15 min were required to 
transfer samples onto the sucrose cushions and start the centrifugation. 
The BSA-containing top fraction together with 300 ill of the sucrose inter- 
face, the remaining sucrose, and the membrane pellet were isolated, and 
their short-chain sphingolipid composition was analyzed. A  phospholipid 
phosphorus determination indicated that saponin did not reduce the effi- 
ciency with which membranes were pelleted. The sucrose fraction never 
contained more than 15%  of the short-chain sphingolipids, and was not 
specifically enriched in any of the sphingolipids. The relative amount of 
each sphingolipid present in the membrane pellet  ("%  protected") was 
calculated as a percentage of the total amount present in pellet and the 
BSA-containing top fraction. 
Destruction of  Fluorescence by Dithionite.  50 p,l of a  1-M stock of so- 
dium dithionite (37) was added, the samples incubated for 5 min on ice 
and the lipids extracted (8). The dithionite concentration required for se- 
lective destruction of NBD-lipid fluorescence should be determined em- 
pirically. It should be noted that the dithionite stock has a short shelf-life, 
and that its activity is only partially inhibited in a 1-phase Bligh and Dyer 
(8) lipid extract (also see reference 3).The relative amount of each sphin- 
golipid present in the dithionite-treated sample (% protected) was calcu- 
lated as a percentage of the total amount present in a control sample not 
treated with dithionite. 
Protease Sensitivity 
Pronase E  treatment was performed as described (28) with some modifi- 
cations. A Golgi-enriched membrane fraction was isolated at the interface 
between 1 ml 1.25 M sucrose and I ml 0.6 M sucrose, 10 mM EDTA in 10 
mM Tris-maleic acid, pH 7.4 (SW60, 30 min, 50,000 rpm, 4°C). Ahquots of 
100 p,l (125 p,g protein) were incubated with 25 Ixg pronase E (20 ixl) for 0, 
5, 10, 15, or 30 rain at 37°C, after which 750 Ixl of ice-cold buffer (50 mM 
NaCI, 10 mM EDTA, 10 mM Tris-maleic acid, pH 7.4) containing 20 mg 
BSA/ml was added. The samples were overlaid on 3 ml 0.5 M sucrose, 10 
mM Tris-maleic acid, pH 7.4, and the membranes pelleted (SW60, 30 min, 
40,000 rpm, 4°C). Pellets were resuspended in 500 i~1 250 mM sucrose, 10 
mM Tris-maleic acid, pH 7.4 (0°C). Sphingolipid synthesis was assayed in 
the presence of MnCI2 for 45 min at 37°C, with 13 nmol NBD-Cer and ei- 
ther UDP-Glc or UDP-Gal, or with 0.6 nmol NBD-GIcCer and UDP-Gal, 
or with 164 pmol HFA-[3H]-Cer, and both UDP-Gal and UDP-Glc. The 
pronase activity is not completely neutralized by the addition of the BSA- 
containing buffer; at 0-min pronase treatment, the activity of the pronase 
sensitive sphingolipid synthesizing enzymes was  reduced  by  ~25%  as 
compared to samples not treated with pronase. In another set of experi- 
ments, the membrane-pelleting step was omitted and protease treatment 
and sphingolipid synthesis occurred  simultaneously: a  Golgi-ER  mem- 
brane fraction was isolated from the PNS of MDCK II cells at the inter- 
face between 1.5 and 0.6 M sucrose. Aliquots were preincubated at 37°C 
for 15 min with pronase E  in the absence or presence of detergent. HFA- 
[3H]-Cer and nucleotide sugars were added (see above), and the samples 
were further incubated for 30 min at 37°C. 
Drug Incubations 
BrefeldinA.  BFA,  dissolved in  ethanol  (100  p,g/ml),  was added  to  the 
growth medium to a final concentration of 1 Ixg/ml (identical results were 
obtained at 5 p,g/ml), and the cells were left in the incubator for I h. Etha- 
nol was added to the control cells. 
PDMP. L,D-threo-PDMP was added from 200-times concentrated stocl~ 
solutions in ethanol, 5 ixl/ml to a final concentration of 0 IxM (only ethanol 
added), 5 ixM, or 50 p,M (in HBSS-Hepes). After a 30-min preincubation 
with PDMP at 10°C (1 ml), HFA-[3H]-Cer (82 pmol per 3-cm dish), NBD- 
Cer (10 nmol), or NFA-[14C]-Cer (8 nmol) was added and the dishes incu- 
bated for 1.5 h at 37°C in the presence of PDMP. Cells and medium were 
analyzed together. 
Tunicamycin. Tunicamycin was added from a stock of 1 mg/ml 10 mM 
NaOH in distilled water. A PNS (250 p,l 1-2 mg protein/ml) was incubated 
for 30 rain at 37°C in the presence of tunicamycin and MnCl2, with 10 
nmol NBD-Cer and either UDP-Glc or UDP-Gal, with 0.5 nmol NBD- 
GlcCer and UDP-Gal, or with 50 pmol HFA-[aH]-Cer and both UDP-GIc 
and UDP-Gal. 
Miscellaneous  Procedures 
BSA Depletion of  Lipid Vesicles. Large  unilamellar egg phosphatidylcho- 
line  vesicles containing 0.3  tool%  N-Rh-PE and  a  total  of 1  mol%  of 
short-chain sphingolipids were prepared in HBSS-Hepes by extrusion of 
freeze-thawed multilamellar vesicles through two stacked polycarbonate 
filters (pore size 200 nm; Nuclepore Corp., Pleasanton, CA) as described 
(36).  The vesicles were incubated with various concentrations of BSA for 
30 min at 20°C, and separated from the (BSA-containing) medium by flo- 
tation:  0.1  ml was mixed with  1.4 ml 53.5%  (wt/vol)  sucrose (10  mM 
Hepes-NaOH,  pH  7.4),  overlayered  with  2  ml  20%  sucrose  (10  mM 
Hepes-NaOH, pH 7.4) and 0.5 ml 10 mM Hepes-NaOH (pH 7.4), and cen- 
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isolated from top to bottom, with volumes of 250, 500, 1,500, 500, and 
1,250 ixl. The vesicles  were efficiently  separated from the (BSA-contain- 
ing) medium collected  in fractions 4 and 5: fractions 1-5 contained 11.5 -+ 
10.1, 69.9 -+ 3.9, 14.2 -+ 4.4, 2.0 -+ 0.6, and 2.5 -+ 1.6% of the nonexchange- 
able  (vesicle)  marker N-Rh-PE (crn.  1 with n  =  3).  Moreover, when an 
NBD-Cer/BSA mixture was centrifuged and subfractionated as described 
above, over 95%  of the NBD-Cer was recovered in fractions 4  and 5. 
Thus, fractions 4  and 5 contained  >95%  of the  (BSA-containing) me- 
dium, and <5% of the vesicles. In the final analysis, the relative amount of 
each sphingolipid present in fractions 4 and 5 ("relative accessibility")  was 
calculated  as a percentage of the total amount present in fractions 1-5. 
Glucose-6-Phosphatase  Latency. As a measure of the intactness of the 
ER, the latency of glucose-6-phosphatase, an integral membrane protein 
with its active center in the lumen of the ER, was determined as described 
(2).  The assay is based on the use of an enzyme substrate, mannose-6- 
phosphate (M6P)  which cannot enter intact  ER.  In short, membranes 
were isolated at the interface between 1.5 M and 0.6 M sucrose in 10 mM 
Hepes-NaOH, pH 7.4 (SW60, 30 min, 50,000 rpm, 4°C). Intact and deter- 
gent-disrupted membranes (0.1%  Triton X-100,  30 min, 0°C) were incu- 
bated for 20 min at 30°C (45 mM Hepes-NaOH, pH 6.5) with or without 1 
mM M6P, and the amount of inorganic phosphate (Pi) released from M6P 
was measured colorimetricaUy.  The latency was calculated as (1 -  Pi re- 
lease from M6P in intact membranes/Pi release from M6P in disrupted 
membranes) ×  100%. 
Results 
• Sphingolipid Galactosylation in HepG2 and 
MDCK H Cells 
HepG2  and  MDCK  II cells were  incubated  with  short- 
chain  NFA-  and  HFA-ceramide  analogs  (Table  I). The 
sphingolipid products were identified based on their colo- 
calization with NBD-lipid  standards  on TLC plates, and 
their identity was confirmed by et- and/or 13-galactosidase 
digestion, and, in the case of sulfatide, by [35S]sulfation  ex- 
periments (58). In addition, experiments on isolated mem- 
branes showed that the glycosphingolipids only formed if 
the  appropriate  nucleotide  sugar  or  sulfate  donor  was 
added (not shown). Based on the short-chain sphingolipids 
that were formed in HepG2 and MDCK II cells (Table I), 
we  decided  to  use  the  NFA-ceramide  analogue  (NBD- 
Cer) and HepG2 cells to study the galactosyltransferases 
synthesizing NFA-GalCer and LacCer. MDCK cells and 
HFA-ceramide were used to characterize the  galactosyl- 
transferases responsible for HFA-GaICer and GaECer. 
The  use  of  MDCK  cells  also  allowed  us  to  examine 
whether NFA-  and  HFA-GaICer are synthesized by the 
same or by different galactosyltransferases. This question 
was addressed by comparing the influence of an inhibitor 
Table L Short-Chain Sphingolipid Synthesis in HepG2 and 
MDCK H Cells 
HepG2  MDCK II 
Enzyme activity  Precursor  Product  NFA  HFA  NFA  HFA 
SM-synthase  Cer  SM  +  +  +  + 
GIcT  Cer  GlcCer  +  +  +  + 
GAIT-  1  Cer  GalCer  +  -  +  + 
GalT-2  ClcCer  LacCer  +  -  -  - 
GaiT-2b  GalCer  Ga2Cer  -  -  -  + 
GST  GaiCer  SGalCer  -  -  -  + 
Intact HepG2 and MDCK II cells were incubated with short-chain NFA-Cer (NBD- 
Cer) or HFA-[3H]-Cer at 37°C, and the sphingolipid products were analyzed as de- 
scribed in Materials and Methods (-, not detected). GlcT, glucosyltransferase; GaiT, 
galactosyltransferase;  GST, GaiCer sulfotransferase. 
of sphingolipid synthesis, PDMP (27), on GalCer synthesis 
from NFA- or HFA-ceramide (Fig.  1).  PDMP efficiently 
inhibited  GIcT activity while  having little  effect on  SM- 
synthase activity. The influence of PDMP on GalCer syn- 
thesis depended on the ceramide used. NFA-GalCer syn- 
thesis was inhibited by PDMP but to a much lesser extent 
than synthesis of GlcCer (A). This result was confirmed in 
experiments using short-chain  [14C]-Cer  instead of NBD- 
Cer as the NFA-ceramide precursor (not shown). In con- 
trast,  the synthesis of HFA-GalCer was not inhibited  by 
the  PDMP  pretreatment  (B).  These  data  confirm  that 
PDMP  is  a  rather  specific inhibitor  of GlcCer synthesis 
(27),  and suggest (but do not prove; see Discussion)  the 
existence of two GalT-l's, one using NFA-ceramide and 
the other using HFA-ceramide as a substrate. 
SubceUular Distribution of 
Sphingolipid Galactosylation 
Most sphingolipid-synthesizing enzymes colocalized at the 
Golgi location of the sucrose gradient (Fig. 2). The pres- 
ence  of these  enzymes in  the  Golgi complex of HepG2 
cells was confirmed by the effects of BFA. BFA induces 
relocation of constituents of the Golgi, with the exception 
of the TGN, to the ER; Golgi relocation is observed in a 
number of cell lines, including HepG2 (but not in MDCK 
II; 30,  53). Earlier experiments demonstrated that ~70% 
of the activity of the Golgi marker enzymes, protein galac- 
tosyltransferase and protein sialyltransferase, and 70% of 
the activity of the sphingolipid glucosyltransferase (GlcT), 
shifted to the ER recovered in fractions 3-5 of the sucrose 
gradient  (53).  Using  the  same  gradient,  Fig.  2  confirms 
o 
oo 
'5 
._> 
<: 
140 I  A 
120 ~ 
lOO 
6ci 
40 
20 
0  '  I  '  I  '  I  '  I  '  I 
0  10  20  30  40  50 
'  [  '  I  '  I  '  I  '  I  ' 
0  10  20  30  40  50 
PDMP (IJM) 
Figure 1.  Inhibition of GalCer synthesis by PDMP in MDCK II 
cells depends on the nature of the ceramide backbone. MDCK II 
cells were preincubated with PDMP, and the activity of SM-syn- 
thase ( -A-,  ~  ), GAIT-1 (--[Sl-, --l-), and GlcT (-O-, --0--) 
was determined at 37°C using NBD-Cer (NFA; A), or HFA-[aH]  - 
Cer (HFA; B). n = 2 with a range smaller than symbol size (un- 
less indicated  otherwise).  100% corresponds to 460 pmol NFA- 
SM, 1.5 pmol NFA-GalCer, 130 pmol NFA-GlcCer (A), and 1.4 
pmol  HFA-SM,  10  pmol  HFA-GalCer,  and  1.7  pmol  HFA- 
GlcCer (B).  The amount of NBD-GalCer formed was close to 
background, but the results in A were confirmed in an indePen- 
dent experiment using 6-cm instead of 3-cm culture  dishes(not 
shown). 
The Journal of Cell Biology, Volume 133, 1996  18 HepG2  MDCK II 
A  D 
^  ^,A 
GIcT  T  30  NFA  7" 
20  '~  I  I 
,  i  ,o  ,  i  10  ' 
0  .Pr  ,  ~  ,  ,  ,  ,  0  ,  ,  ,  ,  '  ,  '  r  -r  ' 
B  Gaff-1  30  E  HFA  7 
20  w 
! 
20  ~  ~  ~ 
lo  E 
o  ~  10 
0  0  .  ,  •  ,  .  ,  .  ,  .  ,  , 
GAIT-2  ~  3o 
40 
20 
so  ~  20 
10  "~  >'  10 
LJ 
0  ~  lo  0 
0  2  4  6  8  10  12  0  2  4  6  8  10  12 
bottom  top  bottom  top 
Fraction  Fraction 
Figure 2.  Subcellular  distri- 
bution  of  glycosphingolipid 
synthesizing  enzymes  in 
HepG2  and  MDCK  II.  A 
PNS  was subfractionated on 
0.7-1.5 M linear sucrose gra- 
dients (density profile, dashed 
line in  C).  In A-C,  HepG2 
cells  were  preincubated  in 
the  absence (open symbols) 
or presence (closed symbols) 
of  BFA,  and  subfractions 
were analyzed for GlcT ac- 
tivity  (A),  GAIT-1 activity 
(B), and GAIT-2 activity (C). 
In  D-F,  subfractions  of 
MDCK  II  cells  were  ana- 
lyzed,  in  D  using  NBD-Cer 
or [14C]-Cer (NFA): SM-syn- 
thase  (NBD,  -A-),  NFA- 
GalT-1  (NBD,  -q:3-;  [14C], 
-~}-),  and  GlcT  (NBD, 
-O-); in E, using HFA-[3H] - 
Cer:  HFA-GalT-1  (-I--); 
and  in  F,  using  HFA-[3H]- 
GalCer:  GalT-2b  (+), 
GST -{~-). The position  of 
the  ER  was  determined  by 
Western blotting with an anti- 
body against  calnexin  (~  in 
E).  N-Rh-PE was  used  as  a 
plasma  membrane  marker 
(dashed line in A and D). En- 
zyme  profiles  were  deter- 
mined  in  at  least two inde- 
pendent  experiments  with 
identical  results;  the  curves 
represent typical experiments. 
these results with respect to GIcT (A), and similar effects 
of BFA were seen on GAIT-1 (B) and GAIT-2 (C), support- 
ing their presence in the Golgi complex. 
The presence of GlcT, GalT-2b, and GST in the Golgi 
complex of MDCK II cells was supported by their colocal- 
ization with SM-synthase (D and F), an enzyme which is 
largely confined to the  Golgi complex of MDCK II cells 
(62). The activity profiles of GIcT and SM-synthase were 
independent of the precursor used, an NFA-ceramide (D), 
or  HFA-ceramide  analogue  (not  shown).  NFA-GalT-1 
also peaked at the Golgi density, and the same result was 
obtained when  instead  of NBD-Cer,  radiolabeled  short- 
chain  NFA-ceramide  was  used  (D).  In  contrast,  HFA- 
GAIT-1 activity peaked near the  bottom of the  gradient 
and  colocalized  with  calnexin  (E),  an  established  ER 
marker (22).  The  same result was obtained when HFA- 
GalT-1 was assayed in the presence of 8 mM CHAPS, or 
when  an  excess  of nonradioactive  short-chain  HFA-Cer 
was included in the assay mixture (not shown). Finally, ex- 
periments  on  intact  MDCK  II  cells  demonstrated  that 
short-chain HFA-GalCer is not synthesized at the cell sur- 
face (58). These data indicate that the sphingolipid synthe- 
sizing enzymes in HepG2 and MDCK II cells are mainly 
present in the Golgi complex, except HFA-GalT-1, which 
appears to localize to the ER of MDCK II cells. 
Topology of Sphingolipid Galactosylation 
in HepG2 Cells 
The topology of NFA-GalT-1 and GalT-2 was determined 
by three approaches using NFA-Cer: (a) the sidedness of 
newly  synthesized  short-chain  sphingolipids  was  deter- 
mined; (b) the sensitivity of the galactosyltransferases to- 
wards  pretreatment  of intact  membranes  with  protease 
was examined, and (c) the galactosyltransferase activities 
were measured after interfering with the import of UDP- 
Gal into the Golgi. 
Sidedness of Short-Chain Products.  As soon as ceramide 
receives  a  hydrophilic  headgroup,  it  loses  the  ability to 
spontaneously traverse lipid bilayers. The topology of the 
newly synthesized  short-chain  sphingolipids  can  then  be 
probed after opening the cells by adding an acceptor for 
Burger et al. Topology of  Sphingolipid Galactosylation  19 short-chain lipids, for example, BSA (28, 62). BSA cannot 
penetrate  intact  membranes  and  will  only  deplete  the 
short-chain sphingolipids present in the cytosolic leaflet of 
organelles. These principles of the BSA sidedness  assay 
were confirmed in experiments on symmetrical lipid vesi- 
cles containing a mixture of short-chain sphingolipids (Ta- 
ble II). At a sufficiently high BSA-to-short-chain lipid mo- 
lar ratio (1,500 in Table II a), BSA depleted most of the 
short-chain ceramides, but not more than 50% of the cera- 
mide derivatives. Fig. 3 A  shows the results obtained on 
HepG2 cells permeabilized with the  pore-forming toxin 
streptolysin-O (1). After allowing NBD-sphingolipid syn- 
thesis in the permeabilized cells at 10°C, a temperature at 
which intracellular membrane traffic is blocked, the buffer 
was  replaced by a  medium  containing BSA.  More than 
85% of NBD-GIcCer was recovered in the BSA-containing 
medium, whereas only 14% of NBD-SM was accessible to 
BSA, fully confirming earlier results (28). In addition, BSA 
depleted  over 92%  of newly synthesized  NBD-GalCer. 
The use of cell homogenates allowed for the simultaneous 
determination of the sidedness of both NBD-GalCer and 
NBD-LacCer (Fig. 3 B). Most NBD-SM and NBD-LacCer 
were protected against depletion by BSA, whereas most 
NBD-GalCer  and  NBD-GIcCer  were  depleted  by  the 
BSA  treatment.  The  same  results  were  obtained  when 
NBD-sphingolipid synthesis was allowed to occur for 30 
min at 37°C instead of 3 h at 10°C (87 +  6% NBD-LacCer 
and 22 +_ 4% NBD-GalCer resisted depletion by BSA). 
Several control experiments were performed to exclude 
a  differential  sensitivity  of  the  individual  NBD-sphin- 
golipid species to depletion by BSA. First, low concentra- 
tions of saponin were used to permeabilize the Golgi and 
allow entry of BSA into the Golgi (43). In the presence of 
saponin, depletion of all four NBD-sphingolipid  species 
was  essentially  complete  (Fig.  3  C).  Second,  the  four 
NBD-sphingolipid species were depleted from lipid vesi- 
cles with similar efficiencies, even at a low BSA-to-short- 
chain lipid molar ratio (Table II b). Finally, when the sided- 
ness  of NBD-lipids  was  determined  using  dithionite,  a 
chemical that cannot easily permeate membranes and de- 
stroys NBD-fluorescence (37), most NBD-SM and NBD- 
Table IL BSA Depletion of Short-Chain Sphingolipids in 
Symmetrical Lipid Vesicles 
Relative accessibility % 
C6-NBD-  C6-HFA-[3H]- 
BSA/short-chain 
lipid molarratio  SM  LacCer  GalCer  GlcCer  Cer  GalCer  GlcCer  Cer 
(a)  0  2  3  2  1  2 
80  29  22  40  40  31 
1500  45  83  50  49  86 
(b)  80  30  29  24  25 
Large unilameUar vesicles prepared from egg-PC, a nonexchangeable marker (N-Rh- 
PE), and a mixture of short-chain sphingolipids (total of 1 mol%) were incubated with 
various concentrations of BSA for 30 min at 20°C. The vesicles were separated from 
the (BSA-contalning) medium by flotation in a sucrose step-gradient, and the relative 
amount of each sphingolipid species present in the medium was determined (flotation 
efficiency >  95%; see Materials and Methods). In a, vesicles contained 0.3 tool% 
NBD-GIcCer, NBD-Cer, I-IFA-[aH]-Cer,  0.01  mol%  HFA-[3H]-GalCer, and 0.001 
tool% I-IFA-[3H]-GIcCer,  in b, 0.2 mol% NBD-SM, NBD-LacCer, NBD-GalCer, and 
NBD-GlcCer. When the latter vesicles were incubated at a BSA-to-short-chain lipid 
molar ratio of 800, 43-44% of the short-chain lipids was accessible to BSA. 
Figure 3.  Sidedness of short-chain sphingolipids in permeabilized 
HepG2 cells and cell homogenates. In A, HepG2 ceils were per- 
meabilized with SLO, and incubated for 3 h at 10°C with NBD- 
Cer and UDP-GIc or UDP-Gal. Subsequently, at t = 0, BSA was 
added and the change in cell-associated NBD-fluorescence  was 
followed in time: SM ( --A--  ), GalCer (-C]-), and GlcCer (--O--); 
100% corresponds to 170 pmol SM (n = 4), 9 pmol GalCer (n = 
2), and 80 pmol GlcCer (n = 4). In a parallel experiment on intact 
cells, BSA depleted 11% of NBD-SM and 14% of NBD-GIcCer 
(average with n = 2; the amount of NBD-GalCer was below the 
detection limit).  In B-D, HepG2 cell homogenates  were incu- 
bated with NBD-Cer at 10°C, and the sidedness of NBD-sphin- 
golipids was assayed, by adding BSA in the absence (B; n = 2) or 
presence of 0.1% saponin (C), or by selective destruction of NBD 
fluorescence  using dithionite  (D; n  =  4). The relative  fluores- 
cence protected against BSA back-exchange or dithionite quench- 
ing is shown; 100% corresponds to 720 pmol SM, 1.5 pmol Lac- 
Cer, 8 pmol GalCer, and 1030  pmol GlcCer. Deviations (range or 
crn.1) smaller than symbol size (unless indicated otherwise); BSA/ 
NBD-lipid molar ratio of 50 (B and C). 
LacCer were protected against dithionite quenching, whereas 
the fluorescence of most NBD-GalCer and NBD-GIcCer 
was destroyed (Fig. 3 D). In conclusion, newly synthesized 
short-chain SM and LacCer are detected in the lumenal 
leaflet, and newly synthesized GlcCer and GalCer in the 
cytosolic leaflet of the Golgi of HepG2 cells. 
Protease Sensitivity.  The sidedness of the enzymes can 
also be tested by determining their sensitivity to externally 
added proteases. Crude Golgi membranes were incubated 
with pronase E, and the effects on NBD-sphingolipid syn- 
thesizing  activity were  followed in  time  (Fig.  4  A).  In 
agreement with earlier results (28), SM-synthase activity 
was  not  inhibited  while  GIcT  activity  was  quickly  im- 
paired.  Sphingolipid galactosyltransferase activities were 
differentially affected by the protease: GAIT-1 activity was 
quickly and almost completely depressed whereas GAIT-2 
activity was not inhibited. These results suggest that the 
active centers of NFA-GalT-I,and GalT-2 are located on 
opposite sides of the Golgi membrane, facing the cytosol 
and the Golgi lumen, respectively. 
Requirement for UDP-Gal Import.  Cytosolic UDP-Gal is 
imported into the Golgi by a specific antiporter (25). Al- 
though both NFA-GalT-1 and GalT-2 require UDP-Gal 
for their activity, only LacCer synthesis should be affected 
by drugs  that  reduce  UDP-Gal  import  into  the  Golgi. 
The fungal toxin tunicamycin has been shown to inhibit 
UDP-Gal  import  into  the  Golgi,  reducing  ganglioside 
GM~ synthesis from GM2 without affecting the activity of 
the  responsible  galactosyltransferase  (65).  As  expected, 
tunicamycin strongly inhibited synthesis of NBD-LacCer, 
while NBD-GlcCer and NBD-GaICer synthesis were not 
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Figure 4.  The effects of protease pretreatment and tunicamycin 
on sphingolipid biosynthesis in the Golgi of HepG2 cells. In A, a 
Golgi membrane fraction was incubated with pronase E at 37°C 
for the indicated  time intervals.  The membranes were reisolated 
and incubated with  NBD-Cer to monitor SM-synthase  (~), 
GlcT (-O-), and GalT-1 (--~-), and with NBD-GlcCer to moni- 
tor GalT-2 ( +  ). In B, a PNS was incubated at 37°C with NBD- 
Cer (solid lines) or NBD-GlcCer (dashed line) in the presence of 
tunicamycin;  GalT-1  (-[~),  GIcT (-(3-),  and  GalT-2  (--~-, 
~).  The curves  represent a typical  experiment; 100% corre- 
sponds to 50 pmol SM, 3 pmol LacCer, 7 pmol GalCer, and 50 
pmol GlcCer (A), and 9 pmol LacCer, 1.1 pmol GalCer, and 300 
pmol GlcCer (B). 
inhibited (Fig. 4 B). The observed increase in NBD-GlcCer 
and  -GalCer synthesis is probably an indirect effect of a 
reduction of SM synthesis by tunicamycin (20% reduction 
at 50 p~g/ml). The opposite effects of tunicamycin on Gal- 
Cer and LacCer synthesis suggest that, in contrast to Lac- 
Cer synthesis, GalCer synthesis does not depend on UDP- 
Gal import into the Golgi lumen. 
NBD-sphingolipid  synthesis  was  also  studied  in  the 
CHO mutants Lec8, deficient in UDP-Gal import into the 
Golgi (16), and Lec2 with normal UDP-Gal import but de- 
ficient  CMP-sialic  acid  import  (17).  These  cells  contain 
wild-type levels of galactosyl- and sialyltransferase activi- 
ties  (12,  16,  17).  The  cell  lines  synthesized  comparable 
amounts of NBD-SM and NBD-GIcCer (Table III). Lec8 
synthesized only slightly less NBD-GalCer than Lec2, but 
no NBD-LacCer could be detected. This result was con- 
firmed in experiments using NBD-GIcCer instead of NBD- 
Cer as the precursor (not shown). These data confirm that 
UDP-Gal import into the Golgi is not required for GalCer 
synthesis. 
Topology of Sphingolipid Galactosylation in 
MDCK H Cells 
MDCK II cells and both NFA- and HFA-ceramide ana- 
logues were used to determine the topology of the galacto- 
syltransferases  NFA-GalT-1  and  GalT-2b  in  the  Golgi, 
and HFA-GalT-1 in the ER,  using the three  approaches 
described for HepG2 cells. 
Sidedness of Short-Chain Products. The sidedness of newly 
synthesized HFA-SM, HFA-GalCer, and HFA-GlcCer in 
Table IlL Sphingolipid Galactosylation in CHO Lec2 and Lec8 
Cell Homogenates 
NBD-lipid synthesis in pmol (and as percent of total) 
Cell line  SM  LacCer  GalCer  GlcCer 
Lec2  278.8 (32.2)  9.1 (1.05)  2.1 (0.24)  574.6 (66.5) 
Lec8  211.9 (31.5)  ND  1.3 (0.19)  458.7 (68.3) 
A PNS (1.6 mg protein/ml) of CHO mutants Lec2 and Lec8 was incubated with NBD- 
Cer, UDP-GIc, and UDP-Gai for 30 rain at 37°C. NBD lipids were quantified as de- 
scribed under Materials and Methods; ND (not detected) indicates fluorescence <0.5 
pmol. 
MDCK II cell homogenates (Table IV) was nearly identi- 
cal to that of the corresponding NFA-lipids in HepG2 cell 
homogenates (Fig. 3) and in MDCK II cell homogenates 
(not  shown).  SM  and  GaECer  were  largely  protected 
against depletion by BSA, while GalCer and GlcCer were 
almost completely depleted. Similar results were obtained 
using a sucrose-Hepes (0.25  M  sucrose, 1 mM EDTA, 10 
mM  Hepes-NaOH, pH 7.4)  instead  of glutamate-Hepes 
homogenization  buffer  (results  not  shown),  and  when 
HFA-sphingolipid synthesis was allowed to occur for 30 
min at 37°C instead of 3 h at 10°C (cf. a and b in Table IV). 
Control experiments were performed to determine the ef- 
ficiency with which the short-chain HFA-sphingolipids are 
depleted by BSA:  after intracellular  synthesis and trans- 
port to the cell surface of intact MDCK II cells at 37°C, all 
lipid species were removed from the cell surface by BSA 
with the same efficiency (58). In addition, experiments on 
lipid vesicles showed that short-chain HFA-sphingolipids 
and NBD-sphingolipids were depleted by BSA with a sim- 
ilar efficiency (Table II a). To exclude the possibility that 
in a cell homogenate a nonphysiological GAIT-1 activity at 
the cytosolic leaflet of the Golgi or ER is boosted by the 
excess of UDP-Gal added to the system, intact cells were 
incubated  with  HFA-ceramide  at  10°C  to  allow  GalCer 
synthesis under more physiological concentrations of UDP- 
Gal. After 3 h, the cells were homogenized and the sided- 
ness of the short-chain products was determined (Table IV 
c). Again, the bulk of HFA-GalCer and HFA-GIcCer was 
accessible to BSA while most of HFA-SM was protected. 
To extend the results obtained on dog kidney MDCK II 
cells to the tissue that in vivo expresses the highest levels 
of GalCer, the sidedness of short-chain HFA-GalCer was 
determined in the rat Schwann cell line, D6P2T (5). The 
Table IV. Sidedness of Short-Chain HFA-Sphingolipids in 
MDCK H and D6P2T Cell Homogenates 
Protected against BSA as percent of total 
(pmol synthesized) 
Synthesis conditions  SM  Ga2Cer  GalCer  GlcCer 
(a) MDCK II, PNS, 10°(2  67 (1.3)  73 (0.03)  14 (1.2)  9  (3.0 
(b) MDCK II, PNS, 37°C  74 (1.3)  88 (0.25)  30 (4.6)  20 (2.1) 
(c) MDCK 1I, intact, 10°C  73 (2.1)  -  31 (2.9)  30 (1.2) 
(d) D6P2T, PNS,  10°C  57 (0.9)  -  11 (0.7)  3 (2.6) 
A PNS of MDCK II cells was incubated with HFA-[3H]-Cer  at 10°C (a), or, in a par- 
allel experiment, at 37°C (b). In c, HFA-[3H]-Cer  was added to intact MDCK II cells 
and after 3 h at 10°C, a PNS was prepared. In d, a PNS of D6P2T cells was incubated 
with HFA-[3H]-Cer  as in a. The sidedness of HFA-sphingolipids  was determined us- 
ing the BSA assay as described in Materials and Methods. The amount of Ga2Cer 
formed at 10°C in intact cells and in D6P2T cell homogenates was below the detection 
limit. The BSA-to-short-chain  lipid molar ratios were > 18,000. 
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Figure 5.  The effects of protease pretreatment and tunicamycin 
on sphingolipid  biosynthesis  in the Golgi and ER of MDCK II 
cells. After pronase treatment and reisolation  of the membranes 
(A),  enzyme activities  were assayed with NBD-Cer (open sym- 
bols)  or  with  HFA-[3H]-Cer  (closed symbols): SM-synthase 
( ~-,  --&-  ), GAIT-1 (-[3-, --ll-), and GlcT (-0-; same result 
using NBD-Cer, not shown). The curves represent typical experi- 
ments. In B, a PNS was incubated at 37°C in the presence of tuni- 
camycin with HFA-[3H]-Cer  to determine the activity of HFA- 
GalT-1  (--I1--), GlcT (--O--), and GalT-2b (-4~).  100% values 
correspond to 120 pmol NFA-SM, 10 pmol NFA-GalCer, 8 pmol 
HFA-SM, 3 pmol HFA-GalCer, and 30 pmol HFA-GlcCer (A), 
and 50 pmol HFA-GalCer, 130 pmol HFA-GlcCer, and 7 pmol 
HFA-Ga2Cer (B; n = 2 with range smaller than symbol size, un- 
less indicated  otherwise). The results of A and B were confirmed 
using HFA-[3H]-Cer in the presence of a 30-fold excess of nonra- 
dioactive HFA-Cer (not shown). 
results  (Table IV d)  were very similar to the  results ob- 
tained  on  MDCK  II cells  (Table  IV a).  In  conclusion, 
newly synthesized short-chain HFA-GalCer is present at 
the cytosolic surface of the ER, and short-chain NFA-Gal- 
Cer at the cytosolic surface of the Golgi. In contrast, newly 
synthesized  short-chain  Ga2Cer remains confined  to  the 
luminal leaflet of the Golgi. 
Protease Sensitivity.  In  agreement with  the  results  ob- 
tained on HepG2 (Fig. 4 A), SM-synthase activity was not 
inhibited by the pronase treatment while GlcT and NFA- 
GalT-1 activity were quickly reduced (Fig. 5 A). Pronase 
treatment  did  not  inhibit  HFA-GalT-1  activity,  and  the 
same result was obtained if trypsin instead of pronase was 
used  (not  shown).  By  omitting  the  membrane  pelleting 
step after protease treatment, the effects of detergent ad- 
dition on the protease sensitivity of HFA-GalT-1 could be 
studied.  HFA-GalT-1 activity was extremely protease re- 
sistant in intact membranes, but became protease sensitive 
after  membrane  solubilization  (Table  V).  These  data 
strongly suggest that HFA-GalT-1 has its active center in 
the lumen of the ER. 
Requirement for UDP-Gal Import.  The effects of tunica- 
mycin on HFA-sphingolipid synthesis were examined (Fig. 
5 B). The synthesis of HFA-GalCer and NFA-GalCer (not 
shown)  were  not  inhibited,  whereas  synthesis  of HFA- 
Ga2Cer was clearly inhibited. With respect to NFA-GalCer 
and HFA-Ga2Cer, these results are in line with the results 
Table V. HFA-GalT-1 Becomes Protease Sensitive after 
Membrane Solubilization 
Protease to membrane  Residual HFA-lipid synthesis activity 
protein ratio  (percent of untreated control) 
Detergent  (wt:wt)  GalCer  GlcCer 
None  1:5  116:8  3.9 
None  1:1  85.5  0.4 
TX-100 (0.1%)  1:5  14.4  - 
TX-100 (0.1%)  1:1  8.4  - 
CHAPS (8 raM)  1:5  64.4  5.1 
CHAPS (8 mM)  1:1  26.1  1.1 
A Golgi-ER membrane fraction from MDCK II cells was preincubated with pronase 
E, in the absence or presence of detergent. Membranes were not reisolated but imme- 
diately incubated with HFA-[3H]-Cer and nucleotide sugars at 37°C. The residual 
HFA-lipid synthesis activity is shown as a percentage of the HFA-lipid synthesis ac- 
tivity in a control sample not treated with pronase. In the untreated controls and in the 
absence of detergent,  100% values corresponded to 2.8 pmol HFA-GalCer and 8.0 
pmol HFA-GlcCer. The addition of Triton or CHAPS changed these values to 2.6 and 
1.2% for HFA-GalCer, and to 0.1  and  10.2% for HFA-GlcCer, respectively. The 
GlcCer signal in the presence of Triton was too low to allow reliable quandtation of 
the effect of pmtease treatment. 
obtained on BSA accessibility and protease sensitivity (Ta- 
ble  IV and  Fig.  5  A),  suggesting  that  NFA-GalCer and 
HFA-Ga2Cer synthesis occur in the cytosolic and lumenal 
leaflet of the Golgi, respectively. The fact that HFA-Gal- 
Cer synthesis was not  inhibited  by tunicamycin suggests 
that the availability of UDP-Gal in the ER lumen is not af- 
fected by tunicamycin (see Discussion). 
Transbilayer Movement of Monohexosyl Sphingolipids 
in ER and Golgi 
If HFA-GalT-1 is  active in the  lumen of the  ER,  HFA- 
GalCer can only become accessible to BSA after translo- 
eating from the lumenal to the cytosolic leaflet of the ER. 
Because such a translocation event is expected to be both 
time-  and  temperature-dependent  (24,  57),  a  PNS  of 
MDCK  II  cells  was  incubated  with  HFA-ceramide  for 
only 30 min at 0°C. BSA was added, and the accessibility 
of HFA-GalCer to BSA was followed in time at 10°C (Fig. 
6). As before (Table IV), most HFA-SM and hardly any 
HFA-GlcCer  was  protected  against  BSA.  However,  al- 
most 50% of HFA-GalCer was protected against BSA at 
the earliest time point (t =  5 min), and only became acces- 
sible after a  prolonged incubation.  As argued before, the 
capacity of BSA to deplete short-chain lipids is very simi- 
lar for all ceramide derivatives tested. In experiments on 
lipid  vesicles,  the  efficiency  with  which  BSA  depleted 
HFA-GalCer and -GlcCer was found to be identical, even 
at a low BSA-to-short-chain lipid molar ratio (Table II a). 
Moreover,  the  luminal  ER  enzyme  glucose-6-phos- 
phatase remained  >93%  latent  during  the  BSA  incuba- 
tion  (Fig. 6),  suggesting that the release of HFA-GalCer 
from the  ER  was not  due  to  a  deterioration  of the  ER 
membrane.  Thus,  the  difference  in  the  percentage  of 
HFA-GalCer  and  the  percentage  of  HFA-GIcCer  de- 
pleted by BSA suggests that HFA-GalCer is synthesized 
in the lumenal leaflet of the ER and translocates to the cy- 
tosolic surface  of the  ER  before it is  depleted  by BSA, 
whereas HFA-GIcCer is synthesized in the cytosolic leaf- 
let (of the Golgi) and is, therefore, immediately accessible 
to BSA. 
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Figure 6.  The accessibility of short-chain HFA-GalCer to BSA in 
MDCK II cell homogenates increases  during a BSA incubation. 
A PNS was incubated with HFA-[3H]-Cer for 30 min at 0°C, and 
the sidedness of newly synthesized HFA-sphingolipids  was deter- 
mined after an incubation with  BSA at 10°C for the indicated 
time intervals  (see Materials  and Methods).  HFA-SM  ( -&- ), 
HFA-GalCer (-II-), and HFA-GIcCer (-0--). The results  of a 
typical experiment are shown; 100% values at t = 5 min (60 min) 
correspond to 0.31 (0.26) pmol HFA-SM, 0.12 (0.14) pmol HFA- 
GalCer, and 0.14 (0.20) pmol HFA-GlcCer. BSA/HFA-lipid mo- 
lar ratio of 18,000. In an independent experiment, the intactness 
of the ER was checked by determining the latency of the lumenal 
ER enzyme, glucose-6-phosphatase  (dashed line; average, n = 2). 
The data presented so far clearly indicate that in anal- 
ogy to LacCer, Ga2Cer is synthesized in the luminal leaflet 
of the Golgi, whereas their direct precursors, with the ex- 
ception of HFA-GalCer, are synthesized in the cytosolic 
leaflet of the Golgi. To follow the transbilayer movement 
of GalCer, cell homogenates were incubated with GalCer, 
the synthesis of higher products was monitored, and their 
sidedness was determined (Table VI). Because the amount 
of higher  products  that  formed turned  out  to  be  highly 
temperature-sensitive,  experiments  were  carried  out  at 
37°C.  By adding PAPS to an MDCK II cell homogenate, 
SGalCer synthesis could now be monitored. In Table VI a, 
an MDCK II cell homogenate was incubated with HFA- 
[3H]-Cer: Ga2Cer and SGalCer were formed, and in both 
cases >80%  was protected against BSA. Direct evidence 
for the translocation of HFA-GalCer to the lumenal leaf- 
let of the  Golgi membrane was obtained by using HFA- 
GalCer as the precursor: Ga2Cer and SGalCer formed and 
both were largely protected  against BSA back-exchange 
(Table  VI  b).  Essentially  the  same  result  was  obtained 
when NBD-GalCer was used as the precursor (Table VI 
c). Convincing evidence for the translocation of GlcCer to 
the lumenal leaflet of the Golgi of HepG2 cells was also 
obtained (Table VI, d  and e). Thus, not only short-chain 
analogues  of GlcCer,  but  also  short-chain  analogues  of 
NFA- and HFA-GalCer are able to translocate from the 
cytosolic to the luminal leaflet of the Golgi, where they are 
used for higher glycosphingolipid synthesis. 
Discussion 
We used short-chain NFA- and HFA-ceramide analogues 
to determine the intracellular  localization and the topol- 
ogy of early sphingolipid galactosylation. The use of NFA- 
ceramide analogues and HepG2 cells offered the opportu- 
nity to directly compare the topology of NFA-GalT-1 and 
GAIT-2, while  NFA-  and  HFA-ceramide  analogues  and 
MDCK  II  cells  allowed  a  comparison  between  NFA- 
GalT-1, HFA-GalT-1, GalT-2b, and GST (see Table I). 
NFA-GaIT- 1 and GaiT-2 Have an Opposite Topology 
Earlier subfractionation experiments indicated that GIcT 
and GAIT-2 are present in the Golgi complex (20, 28, 56), 
and the effects of BFA on the subcellular distribution of 
GlcT and GalT-2 in HepG2 cells (Fig. 2) led us to the same 
conclusion.  Moreover, like  GlcT and  GalT-2, the  NFA- 
GalT-1 activity in  HepG2 cells could be assigned to the 
proximal part of the Golgi complex. With respect to the 
topology of GaiT-2,  our  data  confirmed  the  results  ob- 
tained  by Lannert et al.  (33)  and  lead  to the  conclusion 
that the active center of GAIT-2 is located in the lumen of 
the Golgi. 
An opposite conclusion was reached by Trinchera et al. 
(55), mainly based on a  comparison of intact and deter- 
gent-permeabilized Golgi, and the assumption that Golgi 
permeabilization should boost the activity of lumenal en- 
zymes by increasing their substrate supply. An increase in 
the activity of GalT-2 was not observed, and the authors 
concluded that GAIT-2 is active at the cytosolic surface of 
the Golgi. However, in these types of experiments reliable 
conclusions on enzyme topology can only be drawn if di- 
rect effects of detergent  addition  on enzyme activity are 
excluded. In our hands, (NBD-)LacCer synthesis is strongly 
inhibited  by  detergent  addition  (unpublished  observa- 
tion). The finding that Sepharose-immobilized GlcCer can 
be used by GAIT-2 present in an "intact" Golgi prepara- 
tion (55) may be explained by the presence of inside-out 
or leaky Golgi cisternae;  an  asialofetuin-SAT latency of 
81-84%  (55) indicates that 16--19%  of the Golgi vesicles 
must have been inside-out or leaky. 
In contrast to GAIT-2, NFA-GalT-1 is active at the cyto- 
solic surface of the Golgi complex: NBD-GalCer was ac- 
cessible to BSA, and NFA-GalT-1 activity was rapidly im- 
paired by pronase treatment, the enzyme activity was not 
reduced by tunicamycin, and NBD-GalCer synthesis was 
quite normal in CHO Lec8 cells known to be deficient in 
UDP-Gal import into the Golgi (Figs. 2-4, Table III). Af- 
ter  synthesis  in  the  Golgi  complex,  NBD-GalCer  effi- 
ciently reached the  cell surface of intact HepG2 cells at 
37°C (Burger, K.N.J., unpublished observations). This im- 
plies that  at some stage during  or after transport to the 
plasma membrane, GalCer, like GlcCer, undergoes trans- 
bilayer movement. 
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Golgi 
Incubation conditions  Percent protected against BSA (pmol synthesized) 
Cell line  Precursor  SM  Ga2Cer  SGalCer  GalCer  GlcCer  LacCer 
(a) MDCK II  HFA-[3H]-Cer  82 (3.9)  90 (1.9)  81 (1.4)  37 (14.4)  35 (2.9) 
(b) MDCK II  HFA-GalCer  85 (1.9)  79 (1.6) 
(c) MDCK II  NBD-GalCer  70 (46.0)  84 (10.6) 
(d) HepG2  NBD-GIcCer  88 (47.0) 
(e) HepG2  NBD-GlcCer  7 (47.0) 
A PNS of MDCK II cells was incubated for 30 rain at 37°C with UDP-Gal, PAPS, and HFA-[3H]-Cer (a), HFA-GalCer (b), or NBD-GalCer (c) and the sidedness of newly synthe- 
sized sphingolipids  was determined.  In a similar  experiment, a PNS of HepG2 cells was incubated at 37°C with UDP-Gal and NBD-GlcCer,  and the sidedness of the sphingolipids 
was determined in the absence (d) or presence (e) of 0,1% saponin. The results of a typical experiment are shown. Sidedness determined using BSA; BSA-to-short-chain  lipid  mo- 
lax ratios >20,000 (in a and b) and 700 (in c, d, and e). 
Two Different Ceramide Galactosyltransferase 
Activities in MDCK H Cells 
While HepG2 cells contain only trace amounts of GalCer 
(50),  MDCK II cells contain substantial amounts of Gal- 
Cer and higher derivatives (11, 23, 39). In subfractionation 
experiments  (Fig.  2),  NFA-GalT-1,  GalT-2b,  and  GST 
colocalized at the Golgi location of the sucrose gradient. 
In contrast, HFA-GalT-1  activity was found at a  higher 
density of the gradient, colocalizing with an ER marker. 
Recently, a GalT-1 was cloned from rat brain (47, 48, 51), 
and a number of findings suggests that the HFA-GalT-1 of 
MDCK II cells is the dog homologue of this cloned GalT-1. 
First, Northern blot analysis revealed its presence in the 
nervous system, but also in rat kidney (48,  51).  Second, 
lectin-blotting experiments  on  GAIT-1 purified from rat 
brain suggest a glycoprotein of the high-mannose type, i.e., 
a typical ER resident protein (48). In addition, the protein 
contains an ER retrieval signal KKXX at its COOH termi- 
nus  (see  reference 40).  Proteins with this  double lysine 
motif have occasionally been found to localize to the inter- 
mediate compartment (for review see reference 40),  but 
this is unlikely for HFA-GalT-I: HFA-GalT-1 colocalizes 
with an ER marker at high density of the sucrose gradient 
(Fig.  2),  while, in general, enzymes of the  intermediate 
compartment cofractionate with (trans)Golgi markers at a 
lower density (22,  49).  Finally, cells transfected with the 
GAIT-1 cDNA  have  an increased capacity to synthesize 
GalCer, the enzyme prefers HFA-ceramide as a substrate 
(38, 47; in contrast to the GIcT, 63), and it localizes to the 
ER  (van  der  Bijl,  P.,  G.J.  Strous,  M.  Lopes-Cardozo, J. 
Thomas-Oates, and G. van Meer, manuscript submitted for 
publication). 
The presence of two separate GAIT-1 activities is further 
supported by several findings. First, protease treatment of 
intact  membranes  destroyed  NFA-GalCer  biosynthesis 
while leaving HFA-GalCer biosynthesis unaffected (Fig. 
5). Second, NFA-GalCer biosynthesis was strongly inhib- 
ited by the addition of UDP-GIc to the assay system while 
HFA-GalCer biosynthesis was not affected (Burger, K.N.J., 
and P. van der Bijl, unpublished observations). Finally, a 
potent inhibitor of glucosylceramide biosynthesis, PDMP 
(27),  mildly inhibited NFA-GalCer synthesis, but not the 
synthesis  of HFA-GalCer  (Fig.  1).  In  MDCK  II  cells, 
HFA-GalCer is clearly not synthesized by the GIcT. How- 
ever, our data do not completely exclude this possibility 
for NFA-GalCer: NFA-GalT-1 and GIcT colocalize on a 
sucrose gradient and share the same topology (see below), 
and  NFA-GalCer  synthesis  is  strongly inhibited  in  the 
presence of UDP-Glc. The differential effect of PDMP on 
the synthesis of GlcCer and NFA-GalCer (Fig. 1 A) sug- 
gests the presence of a separate galactosyltransferase re- 
sponsible for the formation of NFA-GalCer, but alterna- 
tive  explanations  are  possible,  for  example,  UDP-Gal 
might interfere with the binding of PDMP to GIcT. The 
question  of the  identity of NFA-GalT-1  is  particularly 
relevant  in  myelin-forming cells,  oligodendrocytes, and 
Schwann cells, which produce large amounts of both NFA- 
and HFA-GalCer, and have a relatively low GIcT activity 
(19,  46).  More  research  will  be  required  to  determine 
whether in these tissues NFA-GalCer is synthesized by a 
separate NFA-GalT-1, by the GlcT, or by the HFA-GalT-1. 
Topology of GalCer-based 
Glycosphingolipid  Biosynthesis and Transbilayer 
Movement of  GalCer 
Our topology studies in MDCK II assign the GalT-2b ac- 
tivity to the  Golgi lumen, and, as in HepG2,  the NFA- 
GAIT-1 activity to the cytosolic surface of the Golgi (Table 
IV, Fig. 5).  The topology of GST was studied less rigor- 
ously,  but  newly  synthesized  short-chain  SGalCer  was 
found protected against BSA back-exchange, directly sup- 
porting the conclusion of Tennekoon et al.  (54)  that sul- 
fatide is synthesized in the  lumenal leaflet of the  Golgi 
membrane. In MDCK II cells, >90% of endogenous Ga2Cer 
and SGalCer contains an NFA-ceramide backbone (39). 
Assuming the NFA-GalT-1 activity detected in vitro is also 
responsible  for the  biosynthesis of NFA-GalCer in vivo, 
our topology results imply that NFA-GalCer must translo- 
cate from the cytosolic to the lumenal leaflet of the Golgi 
membrane in order to become available to GalT-2b and 
GST.  Indeed,  when  NBD-GalCer  was  added  to  intact 
Golgi membranes, it was converted to NBD-GazCer and 
NBD-SGalCer  in  the  lumen  of  the  Golgi  (Table  VI). 
Transbilayer movement is also required for NFA-GalCer 
to  reach  the  cell  surface; newly synthesized short-chain 
NFA-GalCer is transported efficiently to the cell surface 
of intact MDCK II cells (58). 
In contrast to NFA-GalCer, HFA-GalCer is not synthe- 
sized in the Golgi complex but in the ER of MDCK II 
cells.  As  argued  before,  the  HFA-GalT-1  detected  in 
MDCK II cells is closely related to the GAIT-1 cloned from 
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I glycoprotein of 521 amino acids with its active center in 
the  lumen  of the  ER.  It shows significant homology to 
mammalian UDP-glucuronyltransferases, which have their 
active center exposed towards the lumen of the ER in liver 
and kidney (10, 18). A lumenal orientation of HFA-GalT-1 
in the ER of MDCK II cells is supported by our finding 
that in contrast to NFA-GalCer synthesis, HFA-GalCer 
synthesis is only inhibited by protease after membrane sol- 
ubilization (Table V, Fig. 5). 
Short-chain HFA-GalCer appears to have access to the 
cytosolic surface of the ER despite it being synthesized in 
the lumenal leaflet of the ER (Fig. 6). Though most phos- 
pholipids are synthesized in the ER, HFA-GalCer is the 
only glycosphingolipid so far found to be synthesized in 
the ER. Phospholipids, including the sphingolipid SM and 
the  glycophospholipid phosphatidylinositol, are  able  to 
move quickly across the ER  bilayer with a  half-time of 
,~20 min at 37°C; translocation is bidirectional, ATP-inde- 
pendent, protein-mediated, and has a low lipid specificity 
(4,  7,  24,  66).  Future  experiments  will  have  to  resolve 
whether HFA-GalCer uses the same "flippase" that moves 
phospholipids across the ER bilayer. 
Because sugar nucleotides are synthesized in the cytosol 
(13),  the presence of the active center of HFA-GalT-1 in 
the lumen of the ER immediately raises the question how 
UDP-Gal enters the ER lumen. The ER is able to import 
UDP-Glc  (25,  42),  but  UDP-GIc  cannot support  HFA- 
GalCer synthesis (subfractionation experiment; not shown). 
So far, only the Golgi has been found to import UDP-Gal; 
import occurs via an antiport system in which UDP-Gal is 
exchanged with UMP present in the Golgi lumen (for a re- 
view see reference 25).  Our finding that the synthesis of 
HFA-GalCer in the ER is not inhibited by tunicamycin 
(Fig. 5 B) suggests that the mechanism by which UDP-Gal 
enters  the  ER  differs from  that  in  the  Golgi complex. 
However, it is currently unclear how UDP-Gal enters the 
ER lumen. On the one hand, UDP-Gal import was shown 
to be absent in membrane vesicles derived from rat liver 
ER (42),  suggesting that the capacity to import UDP-Gal 
into the ER may only be present in those specialized cell 
types that are capable of synthesizing HFA-GalCer. On 
the other hand, COS and CHO cells transfected with the 
cloned GAIT-1 cDNA efficiently synthesize HFA-GalCer 
(47;  van  der Bijl,  P.,  G.J.  Strous,  M.  Lopes-Cardozo, J. 
Thomas-Oates,  and  G.  van Meer,  manuscript submitted 
for publication) arguing against this possibility. 
After translocation to the cytosolic surface of the ER, a 
second transbilayer movement would be required to make 
HFA-GalCer available to GalT-2b and GST in the lumen 
of the Golgi. This possibility of a reverse translocation of 
HFA-GalCer in the Golgi complex is supported by results 
showing that when short-chain HFA-GalCer is added to 
intact Golgi membranes, it is converted to HFA-Ga2Cer 
and HFA-SGalCer in the lumen of the Golgi (Table VI). 
Though there is no obvious reason why short-chain HFA- 
GalCer would be translocated to the cytosolic surface of 
the  ER  more  efficiently than  endogenous,  long-chain, 
HFA-GalCer (see for example reference  14),  additional 
experiments  are  required  before  our results can  be  ex- 
tended to the behavior of natural HFA-GalCer. Part  of 
the HFA-GalCer synthesized, in vivo, may not translocate 
to the cytosolic leaflet of the ER, and reach the lumenal 
leaflet of the Golgi after vesicular transport. In that case, 
translocation of HFA-GalCer in the Golgi complex would 
not be required for higher glycosphingolipid biosynthesis. 
In contrast, the formation of higher derivatives of NFA- 
GalCer and GlcCer appears  to be absolutely dependent 
on transbilayer movement in the Golgi complex. For simi- 
lar reasons, transport of NFA-GalCer and GlcCer to the 
cell surface depends on transbilayer movement, whereas 
this may not be required for HFA-GalCer. 
Implications  for Biosynthesis and Intracellular 
Transport of Glycosphingolipids 
Fig. 7 combines our experimental data with data from lit- 
erature  to  illustrate  the  steps  involved  in  early  sphin- 
golipid glycosylation and in the intracellular transport of 
glycosphingolipids to the cell surface. The three key fea- 
tures are (1) exposure of newly synthesized monohexosyl 
sphingolipids to the cytosol, (2) translocation of HFA-Gal- 
Cer from the lumenal to the cytosolic leaflet of the ER 
membrane, and (3)  translocation of monohexosyl sphin- 
golipids from the cytosolic to the lumenal leaflet of the 
Golgi membrane. 
All three monohexosyl sphingolipids are, at least tran- 
siently, exposed to the cytosol and may interact with cyto- 
solic  proteins.  First,  the  rather  unexpected  presence  of 
GalCer at the cytosolic surface of the ER and Golgi may 
allow interaction of these organelles with members of the 
large family of cytosolic galactose-binding lectins (6). Sec- 
ond, the monohexosyl sphingolipids at the cytosolic sur- 
face  of  ER  and  Golgi  could,  in  principle,  exchange 
through the cytosol, possibly with the help of transfer pro- 
teins and reach other membranes by a nonvesicular trans- 
port mechanism. Such a  transport mechanism may exist 
for GlcCer in BFA-treated CHO cells: transport of newly 
synthesized SM and GM3 to the plasma membrane was in- 
hibited, but transport of GlcCer was not affected (64). In 
addition, a glycosphingolipid transfer protein has been de- 
scribed which is capable of transferring both GlcCer and 
GalCer from donor to target membranes, in vitro (44, 45). 
However, it is unclear if lipid transfer proteins have a simi- 
lar function in vivo, and kinetic data suggest that, like SM, 
most GlcCer is transported to the cell surface by a vesicu- 
lar mechanism (61).  Finally, the presence of GlcCer and 
GalCer in the cytosolic leaflet of the Golgi complex, im- 
plies  that  these  glycosphingolipids  may  aggregate  and 
form microdomains at the cytosolic surface of the Golgi 
complex. So far, only aggregation of glycosphingolipids in 
the lumenal leaflet of the trans-Golgi network has been 
considered. 
The second important feature of Fig. 7 is the transloca- 
tion of a glycosphingolipid, HFA-GalCer, from the lumi- 
nal to the cytosolic leaflet of the ER membrane (d in Fig. 
7). Preliminary experiments suggest that, in principle, even 
glycosphingolipids with a bulkier headgroup than GalCer 
may be able to move across the ER bilayer: if HepG2 cells 
are treated with BFA to relocate GAIT-2 to the ER (see 
Fig.  2),  a  steep  increase  is  observed  in  the  percentage 
NBD-LacCer accessible to BSA back-exchange (Burger, 
K.N.J., unpublished data). The low sphingolipid content of 
the  ER indicates that most sphingolipids synthesized in 
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for the topology  of early sphin- 
golipid  glycosylation.  The 
formation  of  dihydro-Cer 
(a)  occurs  at  the  cytosolic 
surface  of the  ER  (26,  35). 
Ceramide  undergoes  rapid 
spontaneous  transbilayer 
movement  (b).  HFA-Cer  is 
converted into HFA-GalCer 
in the lumenal leaflet of the 
ER (c), but is able to translo- 
cate  to  the  cytosolic leaflet 
possibly  using  the  bidirec- 
tional  phospholipid  flippase 
(d).  HFA-GalCer  moves  to 
the  Golgi complex in trans- 
port vesicles  (e), or, possibly, 
via monomeric exchange (f). 
NFA-GalCer and GlcCer are 
synthesized  at  the  cytosolic 
face of the Golgi (g and h). 
Monohexosyl  sphingolipids 
are  able to translocate  from 
the cytosolic to the  lumenal 
leaflet  of  the  Golgi  mem- 
brane  (i),  and  act  as  sub- 
strates for enzymes involved 
in  higher  glycosphingolipid 
synthesis  (j, k, and/). Higher 
glycosphingolipids reach  the 
cell  surface  in  the  lumenal 
leaflet  of  transport  vesicles 
(m).  Current  evidence  indi- 
cates  this  route  is  also  fol- 
lowed by the bulk of mono- 
hexosyl  sphingolipids.  The 
same  translocator  in  the 
Golgi (i) may be required for 
both  substrate  supply  to 
higher glycosphingolipid syn- 
thesizing  enzymes,  and  cell 
surface expression of mono- 
hexosyl sphingolipids.  Some 
monohexosyl  sphingolipids 
may reach the cytosolic leaf- 
let of the plasma membrane 
after  vesicular  transport  or 
by monomeric exchange through the cytosol (n).  However, there is currently no evidence supporting the presence of a sphingolipid 
translocator in the plasma membrane (o). Note that the exact intraceUular  distribution of enzymes can only be revealed using immuno- 
EM requiring specific antibodies which are not yet available for the sphingolipid synthesizing enzymes shown. The Golgi enzymes are 
not necessarily present in the same Golgi cisternae, and, in some cell types, part of the enzyme activities may also be present outside the 
ER/Golgi, e.g., at the plasma membrane. Of the enzymes shown, only HFA-GalT-1 has been cloned. Square, galactose; circle, glucose; 
TV, transport vesicle; S, sulfate. 
the Golgi must be excluded from retrograde transport to the 
ER. However, in view of the large size of the retrograde 
transport  pathway,  it  is  unlikely  that  all  sphingolipids 
would be excluded from retrograde traffic. Indeed, Forss- 
man,  a  globoside  synthesized  in  the  Golgi complex,  has 
been detected in the nuclear envelope of MDCK II cells 
by  immunoelectron  microscopy  (60).  Sphingolipids,  like 
Forssman,  that do reach the ER, may have access to the 
cytosolic surface of the ER through the action of the phos- 
pholipid  flippase.  Retrograde  traffic  and  transbilayer 
movement in  the  ER might be  the  mechanism by which 
"luminal" lipids such as the gangliosides GM2 and GM3, and 
the globoside GbnCer reach the cytosol and bind to the cy- 
toskeleton (21, 32). 
The  most  striking  result  of our  topology study  is  the 
ability of all three  monohexosyl sphingolipids  to translo- 
cate from the cytosolic to the luminal leaflet of the Golgi 
membrane  (i  in  Fig.  7).  In  the  translocation  assays,  we 
used  the  conversion  of  monohexosyl  sphingolipids  into 
higher products in the lumenal leaflet of the Golgi as evi- 
dence  for  sphingolipid  translocation.  Although  kinetic 
data cannot be obtained, these assays already reveal some 
The Journal of Cell Biology,  Volume 133, 1996  26 important characteristics of monohexosyl sphingolipid trans- 
location in the Golgi. Translocation of GlcCer and GalCer 
can be uncoupled from their biosynthesis, suggesting that 
separate proteins are responsible for monohexosyl sphin- 
golipid biosynthesis and translocation. In addition, trans- 
location  does not require  cytosolic proteins and is most 
likely  not ATP dependent,  suggesting that  translocation 
occurs through facilitated transport. 
Because the bulk of monohexosyl sphingolipids appears 
to translocate to the luminal leaflet of the Golgi before ar- 
rival at the plasma membrane (61), the same translocator 
in the Golgi is probably required for both substrate supply 
to higher glycosphingolipid synthesizing enzymes, and cell 
surface expression of monohexosyl sphingolipids. Clearly, 
the identification and characterization of the monohexosyl 
sphingolipid translocator(s) will be of great importance in 
understanding  how  cells  regulate  the  glycosphingolipid 
composition of their cell surface. 
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